Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term urothelial carcinoma. Found 8 abstracts

Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 Feb 19;26(8):2241-2256e4.
Ghatalia P, Zibelman M, Geynisman DM, Plimack E. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. Therapeutic advances in medical oncology. 2018 Jul;10:1758835918788310.   PMCID: PMC6066800
Tong C, Daskalakis N, Edwards DC, Cahn DB, Belkoff L, Geynisman DM. Malignant Infiltration of the Penis From Urothelial Carcinoma of the Bladder. Urology. 2017 Sep;107:23-5.   PMCID: Review
Geynisman DM, Handorf E, Wong YN, Doyle J, Plimack ER, Horwitz EM, Canter DJ, Uzzo RG, Kutikov A, Smaldone MC. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer medicine. 2016 Feb;5(2):192-9.   PMCID: PMC4735777
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG, Cairns P. A global profile of gene promoter methylation in treatment-naive urothelial cancer. Epigenetics. 2014 May;9(5):760-73.   PMCID: Pmc4063835
Dreicer R, Li SL, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the Urothelium (E3800) - A trial of the Eastern Cooperative Oncology Group. Cancer. 2007 Aug;110(4):759-63.
Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group. Cancer. 2004 Apr;100(8):1639-45.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term urothelial carcinoma

urothelial carcinoma bladder cancer BLADDER-CANCER immunotherapy Bladder cancer Ctla-4 TRANSITIONAL-CELL-CARCINOMA penile nodule pathology CPG ISLAND METHYLATION mortality DOCETAXEL methylome outcomes field effect CHEMOTHERAPY II TRIAL phase 2 trial transitional cell carcinoma DNA copy alterations Genetics & Heredity INSTABILITY ixabepilone checkpoint blockade DNA METHYLATION Pd-1 CISPLATIN CIMP COMPREHENSIVE GENOMIC CHARACTERIZATION Eli Lilly has served on advisory boards and as consultant for Genentech clonal origins COMBINATION PACLITAXEL Whole-organ map hypermethylation small cell bladder cancer MICROSATELLITE chemotherapy penile metastasis DNA methylation REGIMEN treatment patterns predictive biomarker therapy CELL CARCINOMA founder mutation IFOSFAMIDE Pfizer and Bristol-Myers Squibb and has received institutionally Novartis AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb TRANSITIONAL-CELL CARCINOMA SURVIVAL Immunotherapy vinblastine carboplatin and paclitaxel (CP) regimen Combined Modality Therapy Neoplasm Metastasis doxorubicin HUMAN COLON checkpoint inhibitor MUTATIONS manuscript methods quality of life survival disclosed No writing assistance was utilized in the production of this clonal expansion HYPERMETHYLATION The authors have no other relevant affiliations or financial involvement with any penile carcinoma Urinary Bladder Neoplasms Neoadjuvant Therapy METASTATIC BLADDER-CANCER interest gene signature COLORECTAL-CANCER institutionally directed clinical trial support from Horizon Pharma ER Plimack organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those KeyWords Plus: and cisplatin (M-VAC) regimen MULTICENTER Biochemistry & Molecular Biology TET2 neoadjuvant chemotherapy methotrexate METHOTREXATE MLL3
Last updated on Thursday, June 04, 2020